A Standardized M3Cs clinical validity framework for microRNA data in microRNA databases with application to MicroRNA Childhood Cancer Catalog (M3Cs) version 2.0
Author:
Affiliation:
1. Ahram Canadian University
2. Children Cancer Hospital
3. Armed Forces College of Medicine
4. University of Luxembourg
5. Misr University For Science and Technology
6. Port Said University
7. Ain Shams University
Abstract
The rapid expansion of miRNA research as cancer biomarkers has spurred the development of user-friendly miRNA-disease databases. However, integrating these bioinformatics tools into clinical practice requires innovative approaches. Digital innovation (DIN) represents the innovative link to integrate proposed ‘M3Cs standardized clinical validity framework’ in digital miRNA-disease databases. Our team diligently adhered to the standard workflow of DIN, following each step of the process: Initiate, Develop, Implement, and Exploit. Here we describe a framework for the accurate and standardized clinical validity categorization of miRNAs in databases and validate it by application to the MicroRNA Childhood Cancer Catalog version 2.0 (M3Cs V.2.0) as the product of DIN. The framework provides a semiquantitative measurement for the strength of evidence of a miRNA-disease relationship that correlates to a qualitative classification: "Strong”, “Moderate”, “Limited”, "No Known Trait/Trait subtype Relationship” or "Contradictory Evidence”. Classifications derived from this framework are reviewed and confirmed or adjusted based on clinical expertise of appropriate disease experts. To our knowledge, this is the first catalog to connect miRNAs data with the clinical impact as a validated tool in childhood cancer. We believe that widespread adoption of this framework will lead to improved analysis, interpretation, and integration of miRNA data toward clinical utility.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. H. A comprehensive review of online resources for microRNA-diseases associations: the state of the art;Mahjoubin-Tehran M;Brief. Bioinform.,2022
2. The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility;Bime C;Transl. Res.,2020
3. Rashed, W. M. et al. MicroRNA childhood cancer catalog (M3Cs): a resource for translational bioinformatics toward health informatics in pediatric cancer. Database (Oxford). 2022, (2022).
4. The new organizing logic of digital innovation: An agenda for information systems research;Yoo Y;Inf. Syst. Res.,2010
5. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource;Strande NT;Am. J. Hum. Genet.,2017
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3